Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

NCT07150975 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether GZR18 Injection works as well as the approved weight-loss drug semaglutide (Wegovy®) in reducing body weight over 52 weeks in adults who are obese or overweight.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 420 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-09 · est. completion 2027-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07150975 ↗

Description as written by the study sponsor.

This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this population.

Treatments tested

GZR18 Drug

Administered SC
Semaglutide(Wegovy® ) Drug

Administered SC

Main thing measured	Percentage change in body weight from baseline after 52 weeks (W) of treatment.
Sponsor	Gan & Lee Pharmaceuticals.
Conditions studied	Obesity/Overweight in Adult
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07150975 ↗